Replies to post #241965 on Biotech Values

[sab63090]

Excellent examples, Roy!

[DewDiligence]

MREO -22% on purportedly-positive phase-2 data in AAT deficiency:

https://finance.yahoo.com/news/mereo-biopharma-announces-positive-top-110000754.html

[DewDiligence]

CRBU -34% on purportedly-positive allogeneic-CAR-T data:

https://finance.yahoo.com/news/caribou-biosciences-reports-positive-additional-070000061.html

https://www.evaluate.com/vantage/articles/events/conferences/eha-2022-caribous-turn-run-allo-car-t-relapses

Most patients relapsed within six months. CBRU plans dose escalation to seek a longer duration of response.

The stock is now down about 2/3 from its IPO eleven months ago (https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-pricing-upsized-initial-public ).